File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone

TitleFactors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone
Authors
KeywordsDiabetic macular oedema
Retinal thickening
Triamcinolone acetonide
Visual acuity
Issue Date2009
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEO
Citation
Clinical And Experimental Ophthalmology, 2009, v. 37 n. 6, p. 602-608 How to Cite?
AbstractPurpose: To identify factors associated with variability in anatomical and functional response of diabetic macular oedema (DMO) after 4 mg of intravitreal triamcinolone acetonide (ivTA), and for recurrence of macular oedema. Design: Pooled analysis of individual data from two randomized controlled trials. Methods: This was a multicentre study involving 107 eyes with DMO administered 4 mg ivTA. Predictive factors for response to treatment were evaluated with linear regression analysis. Factors associated with time to recurrence of oedema were studied with Cox proportional hazards modelling. Main outcome measures were maximum improvement in optical coherence tomography (OCT)-measured central foveal thickness (CFT) and best-corrected visual acuity (BCVA), final CFT and BCVA at 12 months and time to oedema recurrence. Results: Greater reduction of retinal thickening occurred in eyes with worse baseline thickening (P < 0.001). There was also greater improvement of visual acuity in eyes with poorer preoperative BCVA levels (P < 0.001). Age, duration of oedema and previous macular laser treatment had no significant effect on maximal BCVA or CFT improvement. Eyes given 4 mg triamcinolone alone were more likely to develop recurrence of oedema at 12 months than those given a combination of 4mg triamcinolone plus sequential laser (hazard ratio 2.60 [95% confidence interval: 1.45-4.67]). Conclusion: Baseline OCT-measured retinal thickening and BCVA are important predictors of maximal anatomical and functional response of DMO to ivTA, respectively. Combination treatment strategy using sequential laser therapy may have a role in delaying recurrence of oedema after triamcinolone. © 2009 The Authors Journal compilation © 2009 Royal Australian and New Zealand College of Ophthalmologists.
Persistent Identifierhttp://hdl.handle.net/10722/86652
ISSN
2023 Impact Factor: 4.9
2023 SCImago Journal Rankings: 1.368
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMohamed, Sen_HK
dc.contributor.authorLeung, GMen_HK
dc.contributor.authorChan, CKMen_HK
dc.contributor.authorLai, TYYen_HK
dc.contributor.authorLee, VYWen_HK
dc.contributor.authorLiu, DTLen_HK
dc.contributor.authorLi, KKWen_HK
dc.contributor.authorLi, PSHen_HK
dc.contributor.authorLam, DSCen_HK
dc.date.accessioned2010-09-06T09:19:40Z-
dc.date.available2010-09-06T09:19:40Z-
dc.date.issued2009en_HK
dc.identifier.citationClinical And Experimental Ophthalmology, 2009, v. 37 n. 6, p. 602-608en_HK
dc.identifier.issn1442-6404en_HK
dc.identifier.urihttp://hdl.handle.net/10722/86652-
dc.description.abstractPurpose: To identify factors associated with variability in anatomical and functional response of diabetic macular oedema (DMO) after 4 mg of intravitreal triamcinolone acetonide (ivTA), and for recurrence of macular oedema. Design: Pooled analysis of individual data from two randomized controlled trials. Methods: This was a multicentre study involving 107 eyes with DMO administered 4 mg ivTA. Predictive factors for response to treatment were evaluated with linear regression analysis. Factors associated with time to recurrence of oedema were studied with Cox proportional hazards modelling. Main outcome measures were maximum improvement in optical coherence tomography (OCT)-measured central foveal thickness (CFT) and best-corrected visual acuity (BCVA), final CFT and BCVA at 12 months and time to oedema recurrence. Results: Greater reduction of retinal thickening occurred in eyes with worse baseline thickening (P < 0.001). There was also greater improvement of visual acuity in eyes with poorer preoperative BCVA levels (P < 0.001). Age, duration of oedema and previous macular laser treatment had no significant effect on maximal BCVA or CFT improvement. Eyes given 4 mg triamcinolone alone were more likely to develop recurrence of oedema at 12 months than those given a combination of 4mg triamcinolone plus sequential laser (hazard ratio 2.60 [95% confidence interval: 1.45-4.67]). Conclusion: Baseline OCT-measured retinal thickening and BCVA are important predictors of maximal anatomical and functional response of DMO to ivTA, respectively. Combination treatment strategy using sequential laser therapy may have a role in delaying recurrence of oedema after triamcinolone. © 2009 The Authors Journal compilation © 2009 Royal Australian and New Zealand College of Ophthalmologists.en_HK
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEOen_HK
dc.relation.ispartofClinical and Experimental Ophthalmologyen_HK
dc.subjectDiabetic macular oedema-
dc.subjectRetinal thickening-
dc.subjectTriamcinolone acetonide-
dc.subjectVisual acuity-
dc.subject.meshAgeden_HK
dc.subject.meshDiabetic Retinopathy - drug therapy - physiopathologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFovea Centralis - pathologyen_HK
dc.subject.meshGlucocorticoids - administration & dosage - therapeutic useen_HK
dc.subject.meshHumansen_HK
dc.subject.meshInjectionsen_HK
dc.subject.meshLaser Coagulationen_HK
dc.subject.meshMacular Edema - drug therapy - physiopathologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPrognosisen_HK
dc.subject.meshProportional Hazards Modelsen_HK
dc.subject.meshRecurrenceen_HK
dc.subject.meshTomography, Optical Coherenceen_HK
dc.subject.meshTriamcinolone Acetonide - administration & dosage - therapeutic useen_HK
dc.subject.meshVisual Acuity - physiologyen_HK
dc.subject.meshVitreous Bodyen_HK
dc.titleFactors associated with variability in response of diabetic macular oedema after intravitreal triamcinoloneen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1442-6404&volume=37&issue=6&spage=602&epage=608&date=2009&atitle=Factors+associated+with+variability+in+response+of+diabetic+macular+oedema+after+intravitreal+triamcinoloneen_HK
dc.identifier.emailLeung, GM:gmleung@hku.hken_HK
dc.identifier.authorityLeung, GM=rp00460en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1442-9071.2009.02104.xen_HK
dc.identifier.pmid19702711-
dc.identifier.scopuseid_2-s2.0-68349144502en_HK
dc.identifier.hkuros163351en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-68349144502&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume37en_HK
dc.identifier.issue6en_HK
dc.identifier.spage602en_HK
dc.identifier.epage608en_HK
dc.identifier.isiWOS:000268587600012-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridMohamed, S=23477897700en_HK
dc.identifier.scopusauthoridLeung, GM=7007159841en_HK
dc.identifier.scopusauthoridChan, CKM=31567525700en_HK
dc.identifier.scopusauthoridLai, TYY=7202203581en_HK
dc.identifier.scopusauthoridLee, VYW=8078995500en_HK
dc.identifier.scopusauthoridLiu, DTL=35337403800en_HK
dc.identifier.scopusauthoridLi, KKW=7404990010en_HK
dc.identifier.scopusauthoridLi, PSH=14219399300en_HK
dc.identifier.scopusauthoridLam, DSC=35500200200en_HK
dc.identifier.citeulike5328518-
dc.identifier.issnl1442-6404-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats